<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T11:08:51Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5600017" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:5600017</identifier>
        <datestamp>2017-09-28</datestamp>
        <setSpec>svn</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Stroke Vasc Neurol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Stroke Vasc Neurol</journal-id>
              <journal-id journal-id-type="hwp">svnbmj</journal-id>
              <journal-id journal-id-type="publisher-id">svn</journal-id>
              <journal-title-group>
                <journal-title>Stroke and Vascular Neurology</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2059-8696</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC5600017</article-id>
              <article-id pub-id-type="pmcid">PMC5600017</article-id>
              <article-id pub-id-type="pmc-uid">5600017</article-id>
              <article-id pub-id-type="pmid">28959492</article-id>
              <article-id pub-id-type="publisher-id">svn-2017-000085</article-id>
              <article-id pub-id-type="doi">10.1136/svn-2017-000085</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Article</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Song</surname>
                    <given-names>Lily</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wang</surname>
                    <given-names>Xia</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Robinson</surname>
                    <given-names>Thompson</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lindley</surname>
                    <given-names>Richard I</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Arima</surname>
                    <given-names>Hisatomi</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">3</xref>
                  <xref ref-type="aff" rid="aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lavados</surname>
                    <given-names>Pablo M</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">6</xref>
                  <xref ref-type="aff" rid="aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chen</surname>
                    <given-names>Xiaoying</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chalmers</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Anderson</surname>
                    <given-names>Craig S</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff3">3</xref>
                  <xref ref-type="aff" rid="aff8">8</xref>
                </contrib>
                <on-behalf-of>for the ENCHANTED Investigators and Coordinators</on-behalf-of>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution>The George Institute for Global Health at Peking University Health Science Center</institution>, <addr-line content-type="city">Beijing</addr-line>, <country>China</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Department of Neurology</institution>, <institution>85 Hospital of People’s Liberation Army</institution>, <addr-line content-type="city">Shanghai</addr-line>, <country>China</country></aff>
              <aff id="aff3"><label>3</label><institution>The George Institute for Global Health, The University of New South Wales</institution>, <addr-line content-type="city">Sydney</addr-line>, <country>Australia</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Department of Cardiovascular Sciences and NIHR Biomedical Research Unit for Cardiovascular Sciences</institution>, <institution>University of Leicester</institution>, <addr-line content-type="city">Leicester</addr-line>, <country>UK</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Department of Preventive Medicine and Public Health</institution>, <institution>Faculty of Medicine, Fukuoka University</institution>, <addr-line content-type="city">Fukuoka</addr-line>, <country>Japan</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Clínica Alemana de Santiago</institution>, <institution>Universidad del Desarrollo</institution>, <addr-line content-type="city">Concepción</addr-line>, <country>Chile</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Departamento de Ciencias Neurológicas</institution>, <institution>Facultad de Medicina, Universidad de Chile</institution>, <addr-line content-type="city">Concepción</addr-line>, <country>Chile</country></aff>
              <aff id="aff8"><label>8</label><institution content-type="department">Neurology Department</institution>, <institution>Royal Prince Alfred Hospital</institution>, <addr-line content-type="city">Sydney</addr-line>, <country>Australia</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Professor Craig S Anderson; <email>canderson@georgeinstitute.org.cn</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>6</month>
                <year>2017</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>22</day>
                <month>5</month>
                <year>2017</year>
              </pub-date>
              <volume>2</volume>
              <issue>2</issue>
              <fpage>53</fpage>
              <lpage>58</lpage>
              <history>
                <date date-type="received">
                  <day>16</day>
                  <month>3</month>
                  <year>2017</year>
                </date>
                <date date-type="rev-recd">
                  <day>29</day>
                  <month>3</month>
                  <year>2017</year>
                </date>
                <date date-type="accepted">
                  <day>02</day>
                  <month>4</month>
                  <year>2017</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</copyright-statement>
                <copyright-year>2017</copyright-year>
                <license license-type="open-access">
                  <license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="svn-2017-000085.pdf"/>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>The characteristics of patients with acute ischaemic stroke (AIS) and their management vary across regions, which may influence outcomes. We examined for differential patterns of outcome between China and non-China participants of the ENhanced Control of Hypertension And Thrombolysis strokE stuDy (ENCHANTED), which tested different alteplase doses in AIS.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>ENCHANTED was an international, multicentre, open, blinded-endpoint trial of the effects of low-dose (0.6 mg/kg) versus standard-dose (0.9 mg/kg) intravenous alteplase on 90-day disability outcomes and symptomatic intracerebral haemorrhage (sICH) in 3310 patients with AIS.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Participants (n=1419, 48%) in China were younger, and more often male, hypertensive and with prior stroke and coronary artery disease, but less likely to have atrial fibrillation and use antihypertensive, antithrombotic and lipid-lowering agents, compared with non-China patients with AIS. Although China participants had more AIS due to large artery occlusion, were treated later and had differing ancillary management, there was no significant difference in 90-day modified Rankin scale scores 2–6 (55.6% vs 47.8%; OR, adjusted for baseline and management factors 0.87 (95% CI 0.71 to 1.07; p=0.20)) and risk of sICH (Safe Implementation of Thrombolysis in Stroke-Monitoring Study criteria: 1.4% vs 1.8%; p=0.12) compared with non-China participants. There was no heterogeneity in the treatment effects of low-dose versus standard-dose alteplase between China and non-China participants.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p>Patients with AIS recruited to the ENCHANTED trial in China had similar outcomes in response to thrombolysis treatment despite significantly differing demographic, clinical and management factors to patients with AIS in other regions.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>acute ischemic stroke</kwd>
                <kwd>intravenous thrombolysis</kwd>
                <kwd>clinical trial</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Council for Scientific and Technological Development of Brazil</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id>
                      <institution>National Health and Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution>Stroke Association of the United Kingdom</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-4">
                  <funding-source>
                    <institution-wrap>
                      <institution>the Ministry for Health, Welfare and Family Affairs of the Republic of Korea</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Stroke is the leading cause of mortality and disability in China. However, Chinese patients with acute ischaemic stroke (AIS) may differ from those in other countries by way of demographic characteristics,<xref rid="R1" ref-type="bibr">1</xref> type of vessel occlusion<xref rid="R2" ref-type="bibr">2</xref> and in the use of alternative therapies such as traditional Chinese medicine and corticosteroids.<xref rid="R3" ref-type="bibr">3</xref> Intravenous alteplase is approved for the treatment of AIS within 4.5 hours of the onset of symptoms,<xref rid="R4" ref-type="bibr">4–6</xref> but Chinese patients are often treated later and with lower doses than in the West.<xref rid="R7" ref-type="bibr">7</xref>
</p>
              <p>The ENhanced Control of Hypertension And Thrombolysis strokE stuDy (ENCHANTED) did not confirm that low-dose alteplase was non-inferior to standard-dose alteplase with respect to the conventional measure of poor outcome, a binary endpoint of death and disability defined by scores of 2–6 on the modified Rankin scale (mRS) at 90 days. However, low-dose alteplase was non-inferior with respect to an ordinal mRS shift analysis and had a significantly lower rate of symptomatic intracerebral haemorrhage (sICH).<xref rid="R8" ref-type="bibr">8–10</xref> Of the 3310 participants, 1419 were recruited from China, and their demographic and disease profile, management and outcome may have been different from that of patients in other countries. We aimed to quantify differences in characteristics, management and response to treatment by country of recruitment (China vs non-China) in the ENCHANTED trial.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods</title>
              <p>The ENCHANTED trial was an international, multicentre, prospective, randomised, open-label, blinded-endpoint trial, the details of which are outlined elsewhere.<xref rid="R8" ref-type="bibr">8–10</xref> In brief, 3310 patients with AIS confirmed on brain imaging and fulfilling local criteria for thrombolysis treatment, including symptom onset within 4.5 hours, were randomly assigned to receive low-dose (0.6 mg/kg; 15% as bolus, 85% as infusion over 1 hour) or standard-dose (0.9 mg/kg; 10% as bolus, 90% as infusion over 1 hour) intravenous alteplase. The study protocol was approved by the appropriate ethics committee at each participating centre, and written informed consent was obtained from each patient or an appropriate surrogate.</p>
              <p>Key demographic and clinical characteristics were recorded at the time of enrolment, with neurological severity measured using the National Institutes of Health Stroke Scale and Glasgow Coma Scale at baseline, 24 hours and at day 7 (or earlier on discharge from hospital). The principal clinical outcome was death or level of disability according to the mRS, which was assessed through telephone or in-person contact by researchers who were blind to the randomised treatment allocation at 90 days. Uncompressed digital images of all baseline and follow-up brain scans—CT, MRI and angiograms—were collected in Digital Imaging and Communications in Medicine (DICOM) format on a CD-ROM identified only with the patient’s unique study number, and uploaded by a special purpose-built, web-based system for central analysis at The George Institute of Global Health. All brain scans with an intracranial haemorrhage were reviewed by at least two independent assessors blind to clinical data, treatment, and date and sequence of scan using MIStar V.3.2 (Apollo Medical Imaging Technology, Melbourne, Victoria, Australia). Assessors graded any haemorrhage as intracerebral, subarachnoid, intraventricular, subdural or other; sICH was graded across all standard definitions.<xref rid="R9" ref-type="bibr">9</xref>
</p>
              <p>Associations of country of recruitment (China vs non-China participants) with death or disability, death and sICH were estimated using logistic regression models with adjustment for confounders. The treatment effects of low-dose versus standard-dose alteplase on death or disability, death and sICH were determined using logistic regression models, and the potential heterogeneity of alteplase dose effect between China and non-China participants was estimated by adding an interaction term to the statistical models. Proportional odds regression models were used to determine the treatment effects on an ordinal shift in mRS scores between China and non-China participants, the proportional odds assumption being fulfilled in all the models.<xref rid="R11" ref-type="bibr">11 12</xref> Data are reported as ORs and 95% CIs. Two-sided p values are reported, with p&lt;0.05 considered statistically significant. SAS V.9.3 was used for analyses.<xref rid="R8" ref-type="bibr">8</xref>
</p>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <sec id="s3a">
                <title>Baseline characteristics and management</title>
                <p>From March 2012 through August 2015, a total of 3310 patients were randomised; 1654 patients were assigned to low-dose alteplase and 1643 to standard-dose alteplase (after exclusion of 13 patients: 9 had no consent, 1 was mistakenly randomised and 3 had duplicate randomisation).<xref rid="R10" ref-type="bibr">10</xref> All 3297 patients (37.8% female; mean age: 66.6 (SD: 12.8) years) were included in these analyses. <xref ref-type="table" rid="T1">Table 1</xref> shows the patient characteristics, split by region, with China participants being younger, and more often male, hypertensive, smokers and with a history of stroke and coronary artery disease, but less likely to have a history of atrial fibrillation and hypercholesterolaemia, and to use antihypertensive, antithrombotic and lipid-lowering agents. Moreover, China participants had a twofold greater risk of large artery occlusion.</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1">Non-China</td>
                        <td align="left" rowspan="1" colspan="1">China</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">p Value</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Time from stroke onset to randomisation (hour)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">2.4 (1.8–3.1)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">3.1 (2.5–3.7)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age (years)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">68.2 (13.4)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">64.3 (11.7)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> ≥80</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">376/1878 (20.0)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">96/1419 (6.8)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Female</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">767/1878 (40.8)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">481/1419 (33.9)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Clinical features</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Systolic BP (mm Hg)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">148.0 (20.5)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">150.9 (18.7)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Diastolic BP (mm Hg)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">82.6 (12.9)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">87.4 (12.5)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Heart rate (beats per minute)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">80.1 (16.4)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">77.5 (13.8)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> GCS score</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1"/>
                        <td valign="bottom" align="left" rowspan="1" colspan="1"/>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  Median (Q1-Q3)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">15.0 (14.0–15.0)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">15.0 (13.0–15.0)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  Severe (3–8)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">48/1878 (2.6)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">88/1419 (6.2)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> NIHSS score</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1"/>
                        <td valign="bottom" align="left" rowspan="1" colspan="1"/>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  Median (Q1-Q3)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">8.0 (5.0–14.0)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">8.0 (5.0–14.0)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">0.11</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">  ≥14</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">490/1878 (26.1)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">363/1419 (25.6)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">0.74</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Medical history</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hypertension</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">1199/1876 (63.9)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">866/1412 (61.3)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">0.13</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Previous stroke</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">293/1878 (15.6)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">296/1419 (20.9)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Coronary artery disease</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">251/1876 (13.4)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">228/1412 (16.1)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">0.03</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Other heart disease (valvular or other)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">171/1876 (9.1)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">64/1412 (4.5)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Atrial fibrillation</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">416/1874 (22.2)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">220/1411 (15.6)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Diabetes mellitus</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">361/1876 (19.2)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">285/1412 (20.2)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">0.50</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Hypercholesterolaemia</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">495/1876 (26.4)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">60/1412 (4.2)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Current smoker</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">401/1872 (21.4)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">369/1412 (26.1)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">0.002</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Prestroke function (mRS)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> No symptoms</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">1439/1875 (76.7)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">1235/1411 (87.5)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> No significant disability</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">436/1875 (23.3)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">176/1411 (12.5)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Medication at time of admission</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Antihypertensive agents</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">980/1876 (52.2)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">518/1412 (36.7)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Warfarin anticoagulation</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">67/1873 (3.6)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">15/1412 (1.1)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Aspirin or other antiplatelet agents</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">565/1873 (30.2)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">187/1412 (13.2)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Glucose-lowering agents</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">245/1873 (13.1)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">171/1412 (12.1)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">0.41</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Statin or other lipid-lowering agent</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">534/1872 (28.5)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">81/1412 (5.7)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Brain imaging features</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> CT scan used</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">1815/1876 (96.7)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">1371/1412 (97.1)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">0.57</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> MRI scan used</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">319/1876 (17.0)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">115/1412 (8.1)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Visible early ischaemic changes</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">598/1876 (31.9)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">173/1412 (12.3)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Visible cerebral infarction</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">503/1876 (26.8)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">240/1412 (17.0)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Visible cerebral infarction with mass effect</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">16/1876 (0.9)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">31/1412 (2.2)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">0.0013</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> CT or MRI angiogram shows proximal occlusion</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">445/1834 (24.3)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">60/1412 (4.2)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Final diagnosis at time of hospital separation</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Non-stroke</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">87/1853 (4.7)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">10/1381 (0.7)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Large artery occlusion due to significant atheroma</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">490/1853 (26.4)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">780/1381 (56.5)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Small vessel or perforating vessel lacunar disease</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">317/1853 (17.1)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">356/1381 (25.8)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Cardioembolism</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">492/1853 (26.6)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">149/1381 (10.8)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Dissection</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">21/1853 (1.1)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">4/1381 (0.3)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Other or uncertain aetiology</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">446/1853 (24.1)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">82/1381 (5.9)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Randomised low-dose treatment</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">946/1878 (50.4)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">708/1419 (49.9)</td>
                        <td valign="bottom" align="char" char="." rowspan="1" colspan="1">0.79</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <p>Data are n (%), mean (SD) or median (IQR). p Values are based on χ<sup>2</sup> test, t-test or Wilcoxon signed-rank test.</p>
                    </fn>
                    <fn id="tblfn2">
                      <p>BP, blood pressure; GCS, Glasgow Coma Scale; mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Differences in alteplase factors and management over the first 7 days are reported in online <xref ref-type="supplementary-material" rid="SP1">supplementary table 1</xref>. China participants who received less alteplase, either as a bolus or infusion dose, were treated much later after symptom onset, and were less likely to receive concomitant treatments, including endovascular clot retrieval, neurosurgery, compression stockings, subcutaneous heparin, intubation and ventilation, an antithrombotic, and stroke unit care and rehabilitation. Conversely, they were more likely to receive intravenous blood pressure-lowering treatment, intravenous traditional Chinese medicine and corticosteroids.</p>
                <supplementary-material content-type="local-data" id="SP1">
                  <object-id pub-id-type="doi">10.1136/svn-2017-000085.supp1</object-id>
                  <caption>
                    <title>Supplementary material 1</title>
                  </caption>
                  <p>
                    <inline-supplementary-material id="ss1" xlink:href="svn-2017-000085supp001.pdf" mimetype="application" mime-subtype="pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
                <p>Across the whole cohort, independent of randomised treatment, and after adjusting for important baseline variables (model 1) and additionally for early management (model 2), country of recruitment was not associated with death or disability at 90 days, whether defined by mRS scores 2–6 (China vs non-China: OR, 0.87; 95% CI 0.71 to 1.07; p=0.20) or mRS scores 3—6 (OR, 1.01; 95% CI 0.81 to 1.26; p=0.93), but was associated with lower mortality (OR, 0.53; 95% CI 0.36 to 0.79; p=0.002) (see online <xref ref-type="supplementary-material" rid="SP1">supplementary table 2</xref>). There was no clear association between country of recruitment and sICH across a broad range of classifications (see online <xref ref-type="supplementary-material" rid="SP1">supplementary table 3</xref>).</p>
                <p>When considering the impact of low-dose versus standard-dose alteplase, there was no significant interaction of the treatment effect by country of recruitment for various 90-day outcomes on the mRS 0–1 vs 2–6, or mRS 0–2 vs 3–6 and mortality alone, or by ordinal shift analysis (<xref ref-type="table" rid="T2">table 2</xref>). Low-dose alteplase was associated with less sICH for all patients, with no significant heterogeneity in such risk between China and non-China participants (see online <xref ref-type="supplementary-material" rid="SP1">supplementary table 4</xref>).</p>
                <table-wrap id="T2" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Randomised treatment effects on major clinical outcomes at 90 days, by non-China versus China</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td valign="top" rowspan="2" align="left" colspan="1">Outcome</td>
                        <td colspan="2" align="left" rowspan="1">Randomised treatment, n (%)</td>
                        <td rowspan="2" align="left" colspan="1">OR (95% CI)</td>
                        <td rowspan="2" align="left" colspan="1">p Value for interaction</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Low-dose</td>
                        <td align="left" rowspan="1" colspan="1">Standard-dose</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Death or disability: mRS scores 2–6</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Non-China</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">505/901 (56.0)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">494/896 (55.1)</td>
                        <td valign="bottom" align="char" char="(" rowspan="1" colspan="1">1.04 (0.86 to 1.25)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.45</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> China</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">350/706 (49.6)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">323/703 (45.9)</td>
                        <td valign="bottom" align="char" char="(" rowspan="1" colspan="1">1.16 (0.94 to 1.43)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Death or major disability: mRS scores 3–6</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Non-China</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">351/901 (39.0)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">357/896 (39.8)</td>
                        <td valign="bottom" align="char" char="(" rowspan="1" colspan="1">0.96 (0.8 to 1.16)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.31</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> China</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">254/706 (36.0)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">235/703 (33.4)</td>
                        <td valign="bottom" align="char" char="(" rowspan="1" colspan="1">1.12 (0.9 to 1.39)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Shift in scores on the mRS</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Non-China</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1"/>
                        <td valign="bottom" align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="(" rowspan="1" colspan="1">0.93 (0.79 to 1.09)</td>
                        <td align="left" rowspan="1" colspan="1">0.15</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  0 (no symptoms at all)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">201/901(22.3)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">183/896(20.4)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  1 (no significant disability despite symptoms)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">195/901(21.6)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">219/896 (24.4)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  2 (slight disability)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">154/901 (17.1)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">137/896 (15.3)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  3 (moderate disability requiring some help)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">130/901 (14.4)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">121/896 (13.5)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  4 (moderate-severe disability requiring assistance with daily living)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">95/901 (10.5)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">72/896 (8.0)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  5 (severe disability, bed-bound and incontinent)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">50/901 (5.5)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">51/896 (5.7)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  6 (death)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">76/901 (8.4)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">113/896 (12.6)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">China</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="char" char="(" rowspan="1" colspan="1">1.1 (0.92 to 1.33)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  0 (no symptoms at all)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">202/706 (28.6)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">214/703 (30.4)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  1 (no significant disability despite symptoms)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">154/706 (21.8)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">166/703 (23.6)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  2 (slight disability)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">96/706 (13.6)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">88/703 (12.5)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  3 (moderate disability requiring some help)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">81/706 (11.5)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">60/703 (8.5)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  4 (moderate-severe disability requiring assistance with daily living)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">70/706 (9.9)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">82/703 (11.7)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  5 (severe disability, bed-bound and incontinent)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">39/706 (5.5)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">36/703 (5.1)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">  6 (death)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">64/706 (9.1)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">57/703 (8.1)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Death during follow-up at 90 days</td>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Non-China</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">76/946 (8.0)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">113/932 (12.1)</td>
                        <td valign="bottom" align="char" char="(" rowspan="1" colspan="1">0.63 (0.47 to 0.86)</td>
                        <td align="char" char="." rowspan="1" colspan="1">0.02</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> China</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">64/708 (9.0)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">57/711 (8.0)</td>
                        <td valign="bottom" align="char" char="(" rowspan="1" colspan="1">1.14 (0.79 to 1.66)</td>
                        <td align="left" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn3">
                      <p>AOR, adjusted OR; mRS, modified Rankin Scale.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>In this secondary analysis of the ENCHANTED trial, there were no significant differences in the important outcomes of death or disability, or sICH, between China and non-China thrombolysis-treated patients with AIS, although China participants had lower overall mortality. The treatment effects of low-dose versus standard-dose alteplase on clinical outcomes and sICH were consistent between China and non-China participants.</p>
              <p>The median time from the onset of symptoms to receipt of treatment was 200 min for China participants, which is longer than recorded in the China national stroke registry<xref rid="R7" ref-type="bibr">7</xref> and trials or quality assurance studies in other countries.<xref rid="R13" ref-type="bibr">13–15</xref> This may have been due to various factors influencing prehospital and posthospital care: delay in the recognition of stroke symptoms, long hospital transfer distances and traffic delays, high cost of alteplase, fear of sICH, and additional efforts required to process the explanation, consent and randomisation aspects of the trial. China participants appear to have been managed less intensively, for example with regard to investigation (cerebral angiogram), intervention (endovascular clot retrieval, neurosurgery), ancillary care (use of compression stocking and subcutaneous heparin), management (intubation and ventilation, stroke unit care) and hospital rehabilitation.</p>
              <p>ENCHANTED was undertaken to resolve uncertainty over the optimal dose of alteplase, as Japanese studies<xref rid="R16" ref-type="bibr">16 17</xref> had indicated low-dose alteplase provides similar, perhaps superior, efficacy and safety to standard-dose alteplase, whereas several observational studies<xref rid="R18" ref-type="bibr">18–23</xref> in China had reported conflicting results. Ultimately, as the only randomised evaluation of different doses of alteplase, ENCHANTED failed to confirm that low-dose alteplase was non-inferior to standard-dose alteplase on primary efficacy outcome, but it did clearly indicate that low-dose alteplase was a safer strategy with a lower risk of sICH. These additional secondary analyses indicate that the efficacy and safety of low-dose versus standard-dose alteplase are consistent between China and non-China participants.</p>
              <p>It is difficult to compare our study with other observational studies<xref rid="R18" ref-type="bibr">18–23</xref> where there are differences in baseline patient characteristics and stroke severity and use of variable alteplase dose regimens.<xref rid="R24" ref-type="bibr">24</xref> A multicentre, multinational study<xref rid="R25" ref-type="bibr">25</xref> involving 591 patients treated at 48 centres in South Korea, China, India and Singapore reported safety and efficacy of standard-dose alteplase in an Asian population.<xref rid="R13" ref-type="bibr">13</xref> Taken together with the current evidence, we consider that standard-dose alteplase should not be excluded as the optimal dose to treat Chinese patients with AIS.</p>
              <p>The strengths of this study are the large sample size and inclusion of patients from a variety of healthcare settings, which enhance the generalisability of the results. The high rates of follow-up, adherence to treatment and rigorous assessment of serious adverse events, especially sICH, ensure that the harms were reliably detected and quantified. However, imprecision in the estimates of the treatment effect may have arisen from interobserver variability in mRS scoring in a pragmatic open trial,<xref rid="R26" ref-type="bibr">26</xref> while the inclusion of patients with generally milder stroke severity treated with a slightly longer delay from symptom onset than has occurred in other trials and evaluations of alteplase in AIS<xref rid="R14" ref-type="bibr">14</xref> may raise concern over the implications of these results. Finally, this was posthoc subgroup analysis, and consequently imprecision and greater potential random error may have limited our ability to detect significant differences.</p>
              <p>In summary, China patients with AIS, as compared with non-China patients with AIS, had different characteristics and management, yet had an increased chance of survival following treatment with alteplase in the ENCHANTED trial. The effects of low-dose versus standard-dose alteplase on all outcomes, including mortality, were similar between China and non-China participants.</p>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> CSA contributed to study design, organisation, execution, statistical review, and review and critique of the report. LS contributed to study execution and writing of the report. XW contributed to data analysis and review and critique of the report. TR and RIL contributed to study design, organisation, execution and review and critique of the report. HA and JC contributed to study design and review and critique of the report. PML and XC contributed to study organisation, execution and review and critique of the report.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> Funding was principally received from the National Health and Medical Research Council (NHMRC) of Australia. Additional funding was from the Stroke Association of the United Kingdom, the National Council for Scientific and Technological Development of Brazil, and the Ministry for Health, Welfare and Family Affairs of the Republic of Korea (HI14C1985).</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> T Robinson is a National Institute of Health Research Senior Investigator, and reports receiving speaking fees from Bayer and Boehringer Ingelheim, and fees for Advisory Panels from Bayer and Daiichi Sankyo. PM Lavados reports receiving research funding from Astra Zeneca, Bayer and Boehringer Ingelheim and speaking fees from Bayer. RI Lindley reports receiving speaking fees from Boehringer Ingelheim, Covidien, and Pfizer. CS Anderson reports receiving fees for Advisory Panels of Astra Zeneca and Medtronic, speaking at seminars for Takeda China and Boehringer Ingelheim, and a research grant from Takeda China. J Chalmers reports research grants and lecture fees from Servier for the ADVANCE trial and post-trial follow-up.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient consent:</bold> Obtained.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Ethics approval:</bold> Every ethics committee at the participating centers.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Data sharing statement:</bold> No data sharing.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>WZ</given-names></name>, <etal>et al</etal></person-group><article-title>Stroke in China: epidemiology, prevention, and management strategies</article-title>. <source>Lancet Neurol</source><year>2007</year>;<volume>6</volume>:<fpage>456</fpage>–<lpage>64</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1474-4422(07)70004-2">doi:10.1016/S1474-4422(07)70004-2</ext-link>
<pub-id pub-id-type="pmid">17434100</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group><article-title>Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study</article-title>. <source>Stroke</source><year>2014</year>;<volume>45</volume>:<fpage>663</fpage>–<lpage>9</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.113.003508">doi:10.1161/STROKEAHA.113.003508</ext-link>
<pub-id pub-id-type="pmid">24481975</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Heeley</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>JG</given-names></name>, <etal>et al</etal></person-group><article-title>Comparison of recovery patterns and prognostic indicators for ischemic and hemorrhagic stroke in China: the ChinaQUEST (QUality Evaluation of Stroke Care and Treatment) Registry study</article-title>. <source>Stroke</source><year>2010</year>;<volume>41</volume>:<fpage>1877</fpage>–<lpage>83</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.110.586909">doi:10.1161/STROKEAHA.110.586909</ext-link>
<pub-id pub-id-type="pmid">20651267</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jauch</surname><given-names>EC</given-names></name>, <name name-style="western"><surname>Saver</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Adams</surname><given-names>HP</given-names></name>, <etal>et al</etal></person-group><article-title>Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source><year>2013</year>;<volume>44</volume>:<fpage>870</fpage>–<lpage>947</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STR.0b013e318284056a">doi:10.1161/STR.0b013e318284056a</ext-link>
<pub-id pub-id-type="pmid">23370205</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demaerschalk</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Kleindorfer</surname><given-names>DO</given-names></name>, <name name-style="western"><surname>Adeoye</surname><given-names>OM</given-names></name>, <etal>et al</etal></person-group><article-title>Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source><year>2016</year>;<volume>47</volume>:<fpage>581</fpage>–<lpage>641</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STR.0000000000000086">doi:10.1161/STR.0000000000000086</ext-link>
<pub-id pub-id-type="pmid">26696642</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><collab>European Stroke Organisation (ESO) Executive Committee</collab>. <article-title>Guidelines for management of ischaemic stroke and transient ischaemic attack 2008</article-title>. <source>Cerebrovasc Dis</source><year>2008</year>;<volume>25</volume>:<fpage>457</fpage>–<lpage>507</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000131083">doi:10.1159/000131083</ext-link>
<pub-id pub-id-type="pmid">18477843</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name>, <etal>et al</etal></person-group><article-title>Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR)</article-title>. <source>Stroke</source><year>2011</year>;<volume>42</volume>:<fpage>1658</fpage>–<lpage>64</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.110.604249">doi:10.1161/STROKEAHA.110.604249</ext-link>
<pub-id pub-id-type="pmid">21512182</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Woodward</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Arima</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group><article-title>Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED)</article-title>. <source>Int J Stroke</source><year>2015</year>;<volume>10</volume>:<fpage>1313</fpage>–<lpage>5</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/ijs.12602">doi:10.1111/ijs.12602</ext-link>
<pub-id pub-id-type="pmid">26283139</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>VK</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group><article-title>Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: an international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment</article-title>. <source>Int J Stroke</source><year>2015</year>;<volume>10</volume>:<fpage>778</fpage>–<lpage>88</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/ijs.12486">doi:10.1111/ijs.12486</ext-link>
<pub-id pub-id-type="pmid">25832995</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lindley</surname><given-names>RI</given-names></name>, <etal>et al</etal></person-group><article-title>Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke</article-title>. <source>N Engl J Med</source><year>2016</year>;<volume>374</volume>:<fpage>2313</fpage>–<lpage>23</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1515510">doi:10.1056/NEJMoa1515510</ext-link>
<pub-id pub-id-type="pmid">27161018</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Woodward</surname><given-names>M</given-names></name></person-group><source>Epidemiology Study Design and Data Analysis</source>. <publisher-loc>America</publisher-loc>: <publisher-name>Chapman &amp; Hall/CRC</publisher-name>, <year>2013</year>.</mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bath</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Lees</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Schellinger</surname><given-names>PD</given-names></name>, <etal>et al</etal></person-group><article-title>Statistical analysis of the primary outcome in acute stroke trials</article-title>. <source>Stroke</source><year>2012</year>;<volume>43</volume>:<fpage>1171</fpage>–<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.111.641456">doi:10.1161/STROKEAHA.111.641456</ext-link>
<pub-id pub-id-type="pmid">22426314</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahlgren</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Dávalos</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group><article-title>Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study</article-title>. <source>Lancet</source><year>2007</year>;<volume>369</volume>:<fpage>275</fpage>–<lpage>82</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(07)60149-4">doi:10.1016/S0140-6736(07)60149-4</ext-link>
<pub-id pub-id-type="pmid">17258667</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emberson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lees</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Lyden</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group><article-title>Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials</article-title>. <source>Lancet</source><year>2014</year>;<volume>384</volume>:<fpage>1929</fpage>–<lpage>35</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(14)60584-5">doi:10.1016/S0140-6736(14)60584-5</ext-link>
<pub-id pub-id-type="pmid">25106063</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><collab>Tissue plasminogen activator for acute ischemic stroke</collab>. <article-title>the National Institute of neurological disorders and Stroke rt-PA Stroke Study Group</article-title>. <source>N Engl J Med</source><year>1995</year>;<volume>333</volume>:<fpage>1581</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">7477192</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Minematsu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nakagawara</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group><article-title>Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II)</article-title>. <source>Stroke</source><year>2010</year>;<volume>41</volume>:<fpage>461</fpage>–<lpage>5</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.109.573477">doi:10.1161/STROKEAHA.109.573477</ext-link>
<pub-id pub-id-type="pmid">20075341</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamaguchi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mori</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Minematsu</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group><article-title>Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT)</article-title>. <source>Stroke</source><year>2006</year>;<volume>37</volume>:<fpage>1810</fpage>–<lpage>5</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/01.STR.0000227191.01792.e3">doi:10.1161/01.STR.0000227191.01792.e3</ext-link>
<pub-id pub-id-type="pmid">16763187</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>CP</given-names></name>, <etal>et al</etal></person-group><article-title>Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study</article-title>. <source>Stroke</source><year>2010</year>;<volume>41</volume>:<fpage>885</fpage>–<lpage>90</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.109.575605">doi:10.1161/STROKEAHA.109.575605</ext-link>
<pub-id pub-id-type="pmid">20224056</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name>, <etal>et al</etal></person-group><article-title>Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients</article-title>. <source>Stroke</source><year>2014</year>;<volume>45</volume>:<fpage>2359</fpage>–<lpage>65</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.114.005245">doi:10.1161/STROKEAHA.114.005245</ext-link>
<pub-id pub-id-type="pmid">24994721</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CH</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>TB</given-names></name>, <etal>et al</etal></person-group><article-title>Optimal dose for stroke thrombolysis in Asians: low dose may have similar safety and efficacy as standard dose</article-title>. <source>J Thromb Haemost</source><year>2012</year>;<volume>10</volume>:<fpage>1270</fpage>–<lpage>5</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1538-7836.2012.04761.x">doi:10.1111/j.1538-7836.2012.04761.x</ext-link>
<pub-id pub-id-type="pmid">22541172</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group><article-title>Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses</article-title>. <source>Stroke</source><year>2014</year>;<volume>45</volume>:<fpage>2354</fpage>–<lpage>8</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.114.005989">doi:10.1161/STROKEAHA.114.005989</ext-link>
<pub-id pub-id-type="pmid">25013020</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pan</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group><article-title>Efficacy and safety of a modified intravenous recombinant tissue plasminogen activator regimen in Chinese patients with acute ischemic stroke</article-title>. <source>J Stroke Cerebrovasc Dis</source><year>2013</year>;<volume>22</volume>:<fpage>690</fpage>–<lpage>3</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2012.08.018">doi:10.1016/j.jstrokecerebrovasdis.2012.08.018</ext-link>
<pub-id pub-id-type="pmid">23111010</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>XY</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Collins</surname><given-names>ML</given-names></name>, <etal>et al</etal></person-group><article-title>Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke</article-title>. <source>J Clin Neurosci</source><year>2010</year>;<volume>17</volume>:<fpage>988</fpage>–<lpage>92</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jocn.2009.12.005">doi:10.1016/j.jocn.2009.12.005</ext-link>
<pub-id pub-id-type="pmid">20510615</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>VK</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>KW</given-names></name>, <name name-style="western"><surname>Venketasubramanian</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group><article-title>Current status of intravenous thrombolysis for acute ischemic stroke in Asia</article-title>. <source>Int J Stroke</source><year>2011</year>;<volume>6</volume>:<fpage>523</fpage>–<lpage>30</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1747-4949.2011.00671.x">doi:10.1111/j.1747-4949.2011.00671.x</ext-link>
<pub-id pub-id-type="pmid">22111797</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rha</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Shrivastava</surname><given-names>VP</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group><article-title>Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW)</article-title>. <source>Int J Stroke</source><year>2014</year>;<volume>9</volume>:<fpage>93</fpage>–<lpage>101</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1747-4949.2012.00895.x">doi:10.1111/j.1747-4949.2012.00895.x</ext-link>
<pub-id pub-id-type="pmid">22988894</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quinn</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Dawson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Walters</surname><given-names>MR</given-names></name>, <etal>et al</etal></person-group><article-title>Reliability of the modified Rankin Scale: a systematic review</article-title>. <source>Stroke</source><year>2009</year>;<volume>40</volume>:<fpage>3393</fpage>–<lpage>5</lpage>. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.109.557256">doi:10.1161/STROKEAHA.109.557256</ext-link>
<pub-id pub-id-type="pmid">19679846</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
